View More Recent Stories

Jan 10, 2025 11:47AM Dyne Therapeutics Inc. (DYN) Reports New Clinical Data Showing Impact on Multiple Measures of Myotonic Dystrophy Type 1
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Jan 2, 2025 07:17AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Dec 30, 2024 11:56AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Dec 12, 2024 04:08PM Baird Starts Dyne Therapeutics (DYN) at Outperform
Dec 2, 2024 12:37PM Piper Sandler highlights Dyne Therapeutics' (DYN) FORCE platform potential
Nov 26, 2024 05:13AM RBC Capital Starts Dyne Therapeutics (DYN) at Outperform
Nov 12, 2024 04:51PM Dynegy (DYN) Misses Q3 EPS by 25c
Oct 24, 2024 03:47AM JPMorgan Downgrades Dyne Therapeutics (DYN) to Neutral
Oct 9, 2024 07:30AM Dyne Therapeutics (DYN) Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
Sep 23, 2024 07:14AM Piper Sandler Reiterates Overweight Rating on Dyne Therapeutics (DYN)
Sep 3, 2024 11:45AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Sep 3, 2024 07:19AM Dyne Therapeutics Inc. (DYN) Declines 20% Following New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251
Sep 3, 2024 06:32AM Dyne Therapeutics Inc. (DYN) Appoints Doug Kerr as CMO
Sep 3, 2024 06:30AM Dyne Therapeutics Inc. (DYN) Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251
Aug 13, 2024 09:05AM Dyne Therapeutics (DYN) PT Raised to $53 at Piper Sandler
Aug 13, 2024 07:05AM Dynegy (DYN) Tops Q2 EPS by 2c
Aug 13, 2024 06:43AM Dyne Therapeutics (DYN) PT Raised to $55 at H.C. Wainwright
Aug 13, 2024 06:39AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Jun 24, 2024 12:31PM Jefferies Reiterates Buy Rating on Dyne Therapeutics (DYN)
Jun 24, 2024 07:32AM Dyne Therapeutics (DYN) Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
Jun 17, 2024 07:25AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
View More Recent Stories